Trial · NCT03499808
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Assess Efficacy by Confirmed Overall Hematologic Response | Isatuximab | 77.1 | 95% Confidence Interval 59.9 to 89.6 | percentage of paticipants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Atrial fibrillation | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Fatigue | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Infections and infestations - Other, specify | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Infusion related reaction | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Lung infection | 2 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Lymphocyte count decreased | 3 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Pancreatitis | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Pruritus | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Skin infection | 1 | Participants | |
| To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab. | Isatuximab | Syncope | 1 | Participants | |
| Overall Survival (24 Month Estimate) | Isatuximab | 85 | 95% Confidence Interval 73 to 97 | percent of participants | |
| Duration of Response (24 Month Estimate) | Isatuximab | 81 | 95% Confidence Interval 67 to 96 | Percent of Participants | |
| Time to Hematologic Response | Isatuximab | 1.1 | 95% Confidence Interval 1 to 3 | Months | |
| Progression-free Survival (24 Month Estimate) | Isatuximab | 74 | 95% Confidence Interval 59 to 88 | percentage of paticipants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03499808/results